PMHNP Scope of Practice for Anxiety in Florida

If you’re a psychiatrist or PMHNP treating anxiety disorders via telehealth, you’re navigating one of the most complicated regulatory landscapes in medicine right now. The rules governing when and how you can prescribe anxiety medications remotely involve a tangled web of federal DEA policy, state medical board regulations, prescription monitoring requirements, and licensing laws that vary dramatically by state.

Here’s the reality: you can legally prescribe controlled anxiety medications via telehealth in 2026 — including benzodiazepines for panic disorder or acute anxiety — but only if you understand which rules apply to your specific situation. Get it wrong, and you’re risking your DEA registration, state license, or worse.

This isn’t theoretical. The DEA proposed rules in 2023 that would have essentially ended telehealth prescribing of controlled substances, triggering over 38,000 public comments from providers who relied on these flexibilities to treat patients. While the DEA backed off and extended COVID-era waivers through December 31, 2025, the regulatory uncertainty remains. And that’s just the federal layer — each state adds its own requirements on top.

Let’s cut through the confusion and look at what you actually need to know to practice safely and legally.

The Federal Foundation: DEA Rules on Telehealth Prescribing

Current Rules (Through 2025)

As of February 2026, federal law still permits you to prescribe Schedule II–V controlled substances via telehealth without an initial in-person exam, thanks to temporary waivers the DEA has extended multiple times since the COVID-19 public health emergency began.

This is a huge deal for anxiety treatment. Before 2020, the Ryan Haight Act (21 U.S.C. §829(e)) effectively required an in-person medical evaluation before prescribing any controlled substance ‘by means of the Internet.’ That meant if you wanted to start a patient on Xanax (alprazolam) or Klonopin (clonazepam) for panic attacks, you either needed to see them in person first or work within extremely narrow exceptions (like the patient being located in a DEA-registered hospital during the teleconsult).

The COVID emergency changed that. The DEA, working with HHS, invoked the public health emergency exception built into the Ryan Haight Act, allowing controlled substance prescribing via telehealth for the first time on a broad scale. Most recently, in November 2024, the DEA announced a third extension through December 31, 2025, keeping these flexibilities alive while they work on a ‘new path forward for telemedicine.’

What this means for your practice: You can currently evaluate a new patient for anxiety via video visit and prescribe a benzodiazepine in that same encounter — no in-person exam required federally. This applies whether you’re prescribing Ativan for acute panic, Xanax for generalized anxiety, or even Schedule II stimulants if you’re treating comorbid ADHD.

What Hasn’t Changed

Even with the temporary waivers, you still need:

• A valid DEA registration in your state of practice
• State licensure where the patient is located (more on this below)
• A legitimate medical purpose and proper documentation of your telehealth encounter
• Standard of care — your telehealth evaluation should be thorough enough to justify the prescription

You’re not exempt from prescribing best practices just because it’s telehealth. Document your clinical rationale, mental status findings, risk assessment, and treatment plan just as you would for an in-person visit.

The Uncertainty Ahead

Here’s where it gets uncomfortable: these flexibilities are temporary. The DEA could change course after 2025. In early 2023, they proposed rules that would have required an in-person visit before prescribing most controlled substances via telehealth (with a limited 30-day ‘buprenorphine exception’ for opioid use disorder treatment). The mental health community pushed back hard, and the DEA postponed implementation.

But the agency hasn’t abandoned the idea. At some point, likely in 2026 or beyond, we’ll see new permanent DEA telemedicine rules. They might require:

• An initial in-person exam before controlled prescribing
• A special ‘telemedicine DEA registration’ (which Congress authorized but DEA never implemented)
• Hybrid care models where you can start treatment remotely but need an in-person follow-up within a certain timeframe

Bottom line: Build your practice with the understanding that fully-remote controlled substance prescribing might not last forever. Some providers are already preparing by establishing relationships with brick-and-mortar clinics where patients can get in-person exams when needed, or by focusing their telehealth practice on non-controlled anxiety medications (SSRIs, SNRIs, buspirone, etc.) which aren’t subject to these restrictions.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Licensing: The Non-Negotiable Requirement

Before you worry about prescribing rules, you need to clear a more fundamental hurdle: you must be licensed in every state where your patients are physically located at the time of treatment.

This is often the biggest surprise for providers new to telehealth. It doesn’t matter if you’re sitting in California — if your patient is in their home in Texas during the video visit, Texas law governs the encounter and you need a Texas medical license (or APRN license if you’re a nurse practitioner).

There are no shortcuts here. A handful of states (like Florida) offer special telehealth registrations for out-of-state providers, but most simply require you to obtain a full license through their standard process.

Multi-State Licensing Options

For Psychiatrists (MDs and DOs):The Interstate Medical Licensure Compact (IMLC) can expedite getting licenses in multiple states. As of 2026, 40 states participate, including Texas, Illinois, Pennsylvania, and Florida among our focus states. Notably, California and New York are NOT in the IMLC, so you’ll go through their conventional (slower) licensing processes.

If you hold a ‘principal license’ in an IMLC state and meet the eligibility criteria (no disciplinary actions, board certification or equivalent, etc.), you can apply for expedited licensure in other IMLC states through a centralized portal. This typically takes 30–60 days instead of 4–6 months.

For PMHNPs:Nurse practitioners face a more complicated landscape. Some states participate in the Nurse Licensure Compact (NLC) for RNs, but APRN (advanced practice) licensure is handled separately in most states. Pennsylvania joined the NLC for RNs in 2022, but that doesn’t automatically grant APRN privileges.

You’ll generally need to obtain an APRN license in each state where you practice, which includes getting state prescriptive authority and often a separate state controlled substance license in addition to your DEA number.

The Economics of Multi-State Practice

Here’s the uncomfortable truth: obtaining licenses in multiple states is expensive and time-consuming. Between application fees ($300–1,000 per state), fingerprinting, continuing education requirements, and the administrative burden, adding a new state can easily cost $1,500–3,000 and take 2–6 months.

This is where platforms like Klarity Health create real value — they often support providers through the multi-state licensing process and ensure you’re only obtaining licenses in states where patient demand justifies the investment. Starting out, many telehealth providers focus on 2–3 high-population states rather than trying to practice nationwide.

Psychiatrists vs. PMHNPs: Critical Scope Differences by State

If you’re a psychiatrist, your scope of practice for treating anxiety is essentially unlimited in every state. You can independently diagnose, provide therapy, prescribe any medication (controlled or not), and make all clinical decisions without oversight. The regulatory complexity for you centers on licensing and prescribing compliance, not scope restrictions.

For PMHNPs, the picture is dramatically different depending on where you practice.

Full Practice Authority States

Good news first: An increasing number of states grant experienced nurse practitioners full independence. Among our focus states:

Illinois — PMHNPs with 4,000+ hours of practice and additional training can apply for Full Practice Authority. Once granted, you can practice completely independently, including prescribing controlled substances, with one exception: if prescribing Schedule II opioids during your first five years of FPA, you must have a physician consultation relationship available (not for other Schedule II drugs like stimulants, and not for Schedule III–V like benzos).

New York — As of 2022, NPs who have completed 3,600 hours of practice under a collaborative agreement can practice independently without physician oversight. For anxiety treatment, this means an experienced NY PMHNP has the same prescriptive authority as a psychiatrist (subject to the same PDMP and e-prescribing rules).

California — This is in transition. AB 890 (passed in 2020) created a pathway for NP independence. Since January 2023, experienced California NPs can practice without physician supervision in certain settings. By January 2026, qualified NPs will be able to practice fully independently in all settings. A California PMHNP meeting the experience requirements will soon have complete autonomy in treating anxiety patients.

Restricted Practice States

Texas — This is where it gets challenging. Texas requires all NPs to work under a Prescriptive Authority Agreement (PAA) with a physician. Your collaborating physician doesn’t need to be on-site or see every patient, but they must be officially responsible for oversight of your practice.

More importantly for anxiety treatment: Texas law prohibits APRNs from prescribing Schedule II controlled substances in outpatient settings except in hospitals or for hospice/palliative care. This means you cannot prescribe stimulants for comorbid ADHD in an anxiety patient via telehealth. You’re limited to Schedule III–V for outpatient prescribing.

For most anxiety disorders, this isn’t a dealbreaker since benzodiazepines (your typical anxiety meds) are Schedule IV. But it’s a significant limitation compared to psychiatrists.

Florida — Florida requires PMHNPs to practice under a physician’s supervisory protocol. The state’s 2020 law granting some NPs independent practice specifically excluded psychiatric specialists — it applied only to primary care NPs.

Florida also has a quirky rule on controlled prescribing: NPs generally cannot prescribe Schedule II substances for more than a 7-day supply, BUT this limit doesn’t apply if you’re a certified ‘psychiatric nurse’ treating a mental illness. So a PMHNP can prescribe Schedule II psychiatric medications (like stimulants for ADHD) without the 7-day limit, but you still need that supervisory protocol with a physician.

Pennsylvania — Requires a collaborative agreement with a physician. Your prescribing authority must be spelled out in that agreement, including controlled substances. Pennsylvania law allows NPs to prescribe:

• Schedule II: up to 30-day supply
• Schedule III–IV: up to 90-day supply

For anxiety treatment with benzodiazepines (Schedule IV), this means you can write prescriptions covering up to 90 days at a time, which is actually pretty reasonable for established patients.

What This Means for Your Practice

If you’re a PMHNP considering telehealth, state scope restrictions will determine where you can practice most effectively. In states like New York or Illinois (once you meet experience requirements), you can operate with full autonomy. In Texas or Florida, you’ll need a platform or employer that provides physician collaboration infrastructure.

Klarity Health and similar platforms typically handle these arrangements, ensuring you have the necessary collaborative agreements in restrictive states. But solo practice is much harder for NPs in those environments — you’d need to find and maintain your own collaborating physician, which often involves fees and complex legal agreements.

Prescription Monitoring Programs: The Hidden Compliance Burden

Every state with our focus operates a Prescription Drug Monitoring Program (PDMP), and most states now mandate that you check it before prescribing controlled substances. This is particularly relevant for anxiety treatment since benzodiazepines are heavily monitored.

Here’s what you need to know:

New York — The I-STOP law requires prescribers to consult the state PMP registry before issuing ANY prescription for Schedule II, III, or IV substances. No exceptions for first-time prescriptions (with very limited exceptions for emergency situations or technical failures). If you’re prescribing Xanax to a new patient, you MUST check the I-STOP database first.

California — Must check the CURES PDMP within 24 hours of initially prescribing a Schedule II–IV drug, and at least every 4 months for ongoing therapy.

Florida — Requires checking E-FORCSE before prescribing any Schedule II–V controlled substance (each new prescription) and at least every 90 days for continued therapy.

Pennsylvania — Mandates PDMP checks before the initial prescription of any opioid or benzodiazepine and for each subsequent prescription. Pennsylvania specifically added benzos to this requirement due to their abuse potential and dangerous interactions with opioids.

Texas — Requires checking the TX PMP before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol (muscle relaxant).

Illinois — Requires registration with the Illinois PMP and consultation for all Schedule II prescriptions. While not explicitly mandated for all Schedule III–V prescriptions, it’s considered best practice to check for benzodiazepines.

The Practical Workflow

In practice, modern EHR and e-prescribing systems integrate PDMP lookups, making this less burdensome than it sounds. Before prescribing a benzo, you’ll typically see a button to ‘Check PMP’ within your prescribing workflow, which queries the state database and shows the patient’s controlled substance history for the past 6–12 months.

You’re looking for red flags: multiple concurrent benzodiazepine prescriptions from different providers, combinations of opioids and benzos, patterns suggesting diversion, etc. Document that you reviewed the PMP and your clinical reasoning if you proceed despite concerning findings.

Failure to check PDMPs is taken seriously — state medical boards have disciplined providers for skipping this step, even when the prescription itself was appropriate.

Electronic Prescribing: The New Standard

Most states now require or strongly encourage e-prescribing, and several mandate it specifically for controlled substances:

California and New York require e-prescribing for ALL medications (controlled or not), with very limited exceptions for technical failures or patient-specific situations.

Florida, Pennsylvania, Illinois, and Texas require e-prescribing for controlled substances specifically, aligning with federal Medicare rules.

For telehealth practices, this is essentially non-negotiable. You’ll need an e-prescribing system that’s DEA-compliant for controlled substances (EPCS — Electronic Prescribing of Controlled Substances). This requires two-factor authentication and other security measures beyond standard e-prescribing.

Most telehealth platforms provide this as part of their infrastructure. If you’re building your own practice, you’ll need to ensure your EHR or standalone e-prescribing solution is EPCS-certified.

State-Specific Telehealth Prescribing Rules

Beyond licensing and general prescribing requirements, some states have specific telehealth rules that affect how you can evaluate and treat anxiety patients remotely:

California

Telehealth-friendly. No mandatory in-person exam required before prescribing via telehealth as long as you conduct an ‘appropriate prior examination’ meeting the standard of care. California law explicitly allows this exam to be done via telehealth, even using asynchronous methods (questionnaires, patient-submitted information) if clinically appropriate — though for psychiatric evaluation and controlled prescribing, real-time video is expected.

Texas

Requires establishing a valid physician-patient relationship through an appropriate telehealth examination, which for new patients must include real-time audio-visual interaction (video visit). You cannot prescribe based solely on a questionnaire or text exchange.

One critical exception: Texas prohibits prescribing Schedule II controlled substances for chronic pain management via telemedicine except in very narrow circumstances. This is aimed at opioids, not anxiety meds, so it shouldn’t affect your psychiatric practice. But it demonstrates Texas’s cautious approach to telehealth prescribing.

Florida

Has detailed telehealth statutes. Key points:

• Must obtain written informed consent from the patient for telehealth treatment (document this in the chart)
• Prohibits prescribing Schedule II controlled substances via telehealth EXCEPT for: (1) treatment of psychiatric disorders, (2) inpatient care, (3) hospice, or (4) nursing home residents

The psychiatric exception is huge — it means you CAN prescribe stimulants for ADHD or any other Schedule II psychiatric medication via telehealth in Florida. But you couldn’t prescribe an opioid for chronic pain remotely.

Florida also offers a special telehealth provider registration for out-of-state clinicians who want to treat Florida patients without obtaining a full Florida license. You must meet eligibility requirements (no discipline, malpractice insurance, etc.) and pay a registration fee, but it’s faster and cheaper than full licensure. Over 1,200 out-of-state providers have used this pathway.

New York

No state-imposed restrictions on telehealth prescribing beyond standard of care requirements. New York regulators have clearly stated that telehealth is acceptable for psychiatric assessment and treatment, including prescribing, as long as technology is adequate for the evaluation.

NY allows audio-only telehealth for mental health services in some circumstances (particularly post-COVID for patients without video access), though video is strongly preferred for initial evaluations and when prescribing controlled substances.

Pennsylvania

Doesn’t have comprehensive telehealth statutes, but the state medical boards have issued guidance: telehealth is permitted if the practitioner obtains information equivalent to an in-person exam. Real-time audio-video is recommended for first evaluations. The boards emphasize that prescribing via telemedicine must meet the same standards as in-person care.

Illinois

Allows and encourages telehealth. No in-person exam requirement — just standard of care. Illinois law explicitly permits mental health services via audio-only telehealth if necessary (e.g., patient doesn’t have video capability), which was made permanent to improve access.

However, federal DEA rules may constrain audio-only prescribing of controlled substances (under current temporary waivers, video is expected for new controlled prescriptions). Best practice: use video whenever possible for thorough mental status exams.

The Economics of Telehealth Anxiety Treatment

Let’s talk about the business reality. If you’re considering joining a telehealth platform versus building your own practice, understanding patient acquisition economics is critical.

The DIY Marketing Reality

Building your own telehealth practice means acquiring patients yourself. Here’s what that actually costs:

SEO (Search Engine Optimization): Getting your website to rank for ‘anxiety psychiatrist [city]’ or ‘telehealth anxiety treatment’ takes 6–12 months of consistent investment before generating meaningful patient flow. You’re competing with established practices, directories, and platforms. Realistic cost: $1,500–3,000/month for professional SEO services, with no guaranteed results.

Google Ads: Mental health keywords are expensive. ‘Anxiety treatment’ or ‘psychiatrist near me’ can cost $15–40+ per click. Most clicks don’t convert to booked appointments. After factoring in click costs, landing page optimization, testing campaigns, and conversion rates, a realistic cost per booked patient through PPC is $200–400+ when you account for no-shows and unqualified leads.

Directory Listings: Psychology Today charges monthly fees and you compete with hundreds of other providers in the same search results. Zocdoc operates on a pay-per-booking model ($35–100+ per new patient) but also charges monthly subscription fees. Total cost per acquired patient when you factor in all expenses: typically $150–300+.

True All-In Cost: When you factor in agency/consultant fees, ad spend testing and optimization, staff time to handle and qualify leads, no-show rates from cold leads, and failed campaigns, acquiring a qualified psychiatric patient through DIY marketing typically costs $200–500+ per patient — and that’s AFTER months of investment before seeing results.

Most solo providers don’t have the expertise, patience, or capital for this approach.

The Platform Economics

Klarity Health uses a pay-per-appointment model where providers pay a standard fee per new patient who books and shows up. This is fundamentally different from the DIY approach:

No upfront marketing spend — You don’t pay $3,000/month hoping for results. You pay only when a patient actually books with you.

Pre-qualified patients — Patients on the platform are already seeking psychiatric care, have been matched to your specialty and availability, and are ready to book. No wasted ad spend on curiosity clicks.

Built-in infrastructure — Telehealth platform, e-prescribing (including EPCS for controlled substances), scheduling, patient intake, and compliance tools are included. You don’t need separate subscriptions for each.

Both insurance and cash-pay patient flow, depending on your preferences.

You control your schedule — Set your availability and only see patients when you want to work.

The math is straightforward: instead of spending $3,000–5,000/month on marketing with uncertain results and 6–12 month ramp-up time, you pay a predictable amount only when you see patients. For most providers, especially those starting out or scaling, this removes the financial risk entirely.

Compliance Best Practices

Here’s how to stay on the right side of regulations:

1. Get Licensed Properly — Don’t cut corners on state licensing. One complaint from a patient in a state where you’re not licensed can trigger board investigations in all your states.

2. Document Thoroughly — Your telehealth notes should demonstrate that you conducted a proper evaluation. Document:

• How you verified the patient’s identity and location
• That you obtained consent for telehealth treatment
• Mental status findings from your video observation
• PDMP check results and your reasoning
• Why the prescribed medication is appropriate

1. Use Video When Possible — Audio-only visits might be permitted in some states for follow-ups, but for initial evaluations and when prescribing controlled substances, use video conferencing. You need to observe the patient’s appearance, behavior, and affect.

2. Check PDMPs Consistently — Make it part of your workflow before prescribing any controlled substance. Most boards audit compliance, and it’s one of the easiest things to verify.

3. E-Prescribe Everything — In 2026, there’s no reason to write paper prescriptions for routine care. Use EPCS-certified systems for controlled substances.

4. Keep Up with Regulations — Subscribe to updates from your state medical boards and the DEA. Join professional organizations (APA, AANP) that track regulatory changes and advocate for provider-friendly policies.

5. Have Emergency Protocols — Know how to handle a patient in crisis during a telehealth visit. Have procedures for contacting local emergency services in the patient’s location if needed.

6. Informed Consent — Document that you’ve explained telehealth limitations to patients, obtained their consent, and discussed what to do if technical problems occur during treatment.

FAQ: Telehealth Prescribing for Anxiety

Can I prescribe benzodiazepines via telehealth in 2026?

Yes, under current federal rules (extended through December 31, 2025 and likely beyond), you can prescribe Schedule IV benzodiazepines like Xanax, Ativan, or Klonopin after a telehealth evaluation without an in-person exam. However, you must be licensed in the patient’s state, conduct an appropriate evaluation (typically via video), check your state’s PDMP, and comply with state-specific prescribing rules.

Do I need a DEA registration in every state where I practice telehealth?

No. You need one DEA registration in the state where you’re physically located when prescribing. However, you DO need a medical or APRN license in every state where your patients are located during treatment.

What’s the difference between psychiatrist and PMHNP prescribing authority for anxiety?

Psychiatrists have full independent prescribing authority in all states with no supervision requirements. PMHNPs’ authority varies by state — some states grant full independence after meeting experience requirements (NY, IL, CA soon), while others require physician collaboration agreements (TX, FL, PA). Some states also limit NP prescribing of Schedule II controlled substances.

Can I prescribe anxiety medications after just an audio-only phone call?

Generally, no. Current best practice and most state regulations expect video conferencing for initial evaluations and controlled substance prescribing. Some states (like Illinois) permit audio-only for mental health services if video isn’t accessible, but federal DEA rules currently expect video for new controlled prescriptions. Audio-only might be acceptable for follow-up visits with established patients in some states.

How do I handle PDMP requirements across multiple states?

You must register with and check the PDMP in each state where you’re prescribing controlled substances. Many modern EHR systems integrate multi-state PDMP access, or you can use services like RxCheck that aggregate multiple state databases. Budget time before each controlled prescription for this check — it’s not optional.

What happens if DEA rules change after 2025?

If the DEA finalizes new telemedicine rules requiring in-person exams, you’ll need to adapt your practice. Options might include: establishing relationships with local clinics where patients can get in-person evaluations, shifting your telehealth practice toward non-controlled anxiety medications (SSRIs, SNRIs, buspirone), working with a hybrid model, or obtaining a special telemedicine DEA registration if that pathway is created. Stay connected with professional organizations that will advocate for provider-friendly rules.

Can I practice across state lines without multiple licenses?

No. You must be licensed in every state where patients are located during treatment. The Interstate Medical Licensure Compact (IMLC) can expedite multi-state licensing for physicians in participating states, but there’s no shortcut to avoid state licensure requirements entirely.

How do I get reimbursed for telehealth anxiety treatment?

Most states now have insurance parity laws requiring coverage of telehealth equivalent to in-person care. Medicare covers telepsychiatry widely. The bigger question is whether you want to credential with insurance panels yourself or work with a platform that handles billing. For cash-pay, you set your own rates — typical market rates for psychiatric visits range from $200–400 for initial consultations and $100–200 for follow-ups, depending on your market and experience.

Why Klarity Makes Sense for Anxiety Specialists

If you’re a psychiatrist or PMHNP focused on anxiety treatment, joining Klarity’s platform solves the major business and regulatory headaches that make independent telehealth practice so challenging:

Patient Acquisition Without Gambling — You skip the $200–500+ per-patient marketing costs and 6–12 month wait for SEO results. Qualified patients matched to your expertise book directly with you.

Multi-State Practice Support — Klarity handles the complexity of multi-state compliance, including ensuring you have necessary collaborative agreements in states that require them for NPs.

Built-In Infrastructure — EPCS-capable e-prescribing, HIPAA-compliant telehealth platform, scheduling, documentation tools, and patient intake are all included.

Predictable Economics — Pay-per-appointment model means you only pay when you see patients. No monthly marketing burn or subscription fees hoping for results.

Focus on Clinical Care — Instead of spending time on marketing, credentialing, platform management, and compliance paperwork, you spend time treating patients.

For many providers, particularly those starting out in telehealth or looking to scale without the operational burden, platforms like Klarity represent the economically rational choice. You maintain clinical autonomy while offloading the business infrastructure that most clinicians didn’t train for and don’t enjoy.

Take the Next Step

If you’re a licensed psychiatrist or PMHNP with experience treating anxiety disorders, explore joining Klarity’s provider network. You’ll get access to patients seeking anxiety treatment across multiple states, with the infrastructure and support to practice compliantly while maximizing your clinical time.

The regulatory landscape for telehealth prescribing will continue evolving, but the demand for accessible, quality anxiety treatment isn’t going anywhere. Position yourself to meet that demand with the right support structure in place.

Citations and References

1. DEA & HHS Telemedicine Extension Announcement – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (November 15, 2024) – https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. 21 U.S.C. § 829(e) and § 802(54) (Ryan Haight Act provisions) – Federal controlled-substance prescribing requirements – https://www.law.cornell.edu/uscode/text/21/829

3. Center for Connected Health Policy – ‘State Telehealth Policies for Online Prescribing’ (Updated January 9, 2026) – https://www.cchpca.org/topic/online-prescribing/

4. Florida Statutes – F.S. 456.47 (Telehealth Services) and F.S. 464.012 (Advanced Practice Registered Nurses) – http://www.leg.state.fl.us/Statutes/

5. New York Department of Health – I-STOP/PDMP Program (Effective August 27, 2013) – https://health.ny.gov/professionals/narcotic/prescription_monitoring/

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94